Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00078130" target="_blank" >RIV/00216224:14110/14:00078130 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1158/2159-8290.CD-14-0001" target="_blank" >http://dx.doi.org/10.1158/2159-8290.CD-14-0001</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1158/2159-8290.CD-14-0001" target="_blank" >10.1158/2159-8290.CD-14-0001</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

Popis výsledku v původním jazyce

Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models. Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies.

Název v anglickém jazyce

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

Popis výsledku anglicky

Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models. Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cancer Discovery

ISSN

2159-8274

e-ISSN

—

Svazek periodika

4

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

16

Strana od-do

998-1013

Kód UT WoS článku

000343121400023

EID výsledku v databázi Scopus

—